this is to investigate the difference in outcomes between Intravitreal injection of Bevacizumab and Aflibercept (Eylea) Injection for ROP treatment in premature infants.

Retinopathy Of Prematurity in preterm infants is an important disease which can be control with well-timed intervention. While IVB has received FDA approve for systemic treatment of several cancer, it has been used as an off-label agent for ocular diseases.

In this study we investigated 45 premature infants from 1395 Isfand until 1396 Aban who needed ROP treatment. According to their disease progression they were underwent intravitreal injection treatment. 27 eyes get Eylea and 18 eyes received IVB. After at least three months of follow ups we did not detect any significant difference between IVB and Eylea short-term outcomes.

Although Eylea is an FDA-Approved medication that is administered by an injection into the eye to treat certain retina disease, it is a placental growth factor and may have side effects in newborns which should consider in further studies.